Email this article LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?
- Authors: Matveev V.B.1, Volkova M.I.1, Kupchan D.Z.1, Gridneva Y.V.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 6, No 4 (2010)
- Pages: 71-77
- Section: PROSTATE CANCER
- Published: 30.12.2010
- URL: https://oncourology.abvpress.ru/oncur/article/view/367
- DOI: https://doi.org/10.17650/1726-9776-2010-6-4-71-77
- ID: 367
Cite item
Full Text
Abstract
Eligard (leupropelin acetate, Atrigel delivery system) is a synthetic analogue of luteinizing-hormone-realizing hormone (LHRH), which causes a rapid reduction in the level of testosterone to the concentration comparable with that after surgical castration. Eligard demonstrated a considerable advantage over other LHRH analogues in the depth of androgenic suppression and in the frequency of transient increases in testosterone levels at the beginning and during therapy. Eligard is available as 1-, 3-, and 6-month depot formulations, which allows a flexible approach to be applied to individually making up a therapy regimen. Eligard is as effective as castration therapy techniques. Treatment with this drug shows the low frequency of side effects and is well tolerated by patients.
About the authors
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: mivolkova@rambler.ru
Russian Federation
M. I. Volkova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: mivolkova@rambler.ru
Russian Federation
D. Z. Kupchan
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: mivolkova@rambler.ru
Russian Federation
Ya. V. Gridneva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: mivolkova@rambler.ru
Russian Federation
References
Supplementary files
